Breaking News: FDA Approves Tovorafenib (Ojemda®) for Pediatric LGG with BRAF Mutations
A Wonderful Day for pLGG patients and their families
This afternoon, the FDA granted Accelerated Approval to Day One Biopharmaceuticals (Nasdaq: DAWN) tovorafenib (Ojemda®) for relapsed or refractory pediatric LGG harboring a BRAF mutation (see here). The news is so fresh that, as I write this post, Day One has yet to issue a formal press release, although there is an exploding fireworks overlay on the DAWN website. Stay tuned for further information.
A wonderful day for pediatric brain cancer patients, their families and care teams, and the dedicated people at DAWN.
Special shout out to Sam Blackman, Julie Grant, and the entire team of visionaries at DAWN who brought this innovation to life and developed it to serve patients. Many thanks to the patients, caregivers and physicians who participated in the clinical studies required to register the Ojemda®.